Outcome of Board Meeting held on April 27, 2026
As filed · Outcome of Board Meeting held on April 27, 2026.
What happened
FactROSSARI Biotech Limited's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026, during a meeting on April 27, 2026. The Board also declared a final dividend of 25% (0.50 per share) on equity shares for the financial year 2025-26, which will be paid within 10 working days after the upcoming Annual General Meeting, pending approval from the company's members. Further details regarding the record date for the…
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
Delayedwe should see this part of this ramp-up happening this year and a full-scale premix facility capacity enhancement in the next year.
The CAPEX plan for this year would be I think anything between Rs. 50 crore to Rs. 75 crore, that is the plan.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- the other capex which we have announced, they are going to come over the next, about a year or so. (management committed by H1 FY27)
- I think we should be at a level of at least twice of what we currently are. (management committed by FY25)
Evidence
- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%